Intech Investment Management LLC Grows Stake in Jazz Pharmaceuticals PLC $JAZZ

Intech Investment Management LLC grew its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 77.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 18,792 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,180 shares during the quarter. Intech Investment Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,195,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Baker Avenue Asset Management LP purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $244,000. Hantz Financial Services Inc. boosted its position in shares of Jazz Pharmaceuticals by 73.5% in the 4th quarter. Hantz Financial Services Inc. now owns 2,320 shares of the specialty pharmaceutical company’s stock valued at $394,000 after purchasing an additional 983 shares during the period. Simplify Asset Management Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $12,100,000. Systematic Financial Management LP boosted its position in shares of Jazz Pharmaceuticals by 0.6% in the 4th quarter. Systematic Financial Management LP now owns 396,877 shares of the specialty pharmaceutical company’s stock valued at $67,469,000 after purchasing an additional 2,536 shares during the period. Finally, Swedbank AB boosted its position in shares of Jazz Pharmaceuticals by 2.7% in the 4th quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock valued at $187,506,000 after purchasing an additional 28,882 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director owned 384,682 shares in the company, valued at approximately $73,281,921. This represents a 1.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,287 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,028 shares of company stock worth $2,522,587 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $232.64 on Tuesday. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The company has a market capitalization of $14.60 billion, a P/E ratio of -11,626.19, a PEG ratio of 0.41 and a beta of 0.32. The business has a 50 day moving average price of $209.13 and a 200 day moving average price of $184.57. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion during the quarter. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 21.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on JAZZ. Royal Bank Of Canada upped their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Sanford C. Bernstein began coverage on Jazz Pharmaceuticals in a research report on Thursday, May 21st. They issued a “market perform” rating and a $229.00 target price for the company. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. TD Cowen upped their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Piper Sandler upped their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $242.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.